Search

Your search keyword '"Kalarus, Zbigniew"' showing total 37 results
Start Over Author "Kalarus, Zbigniew" Publisher elsevier b.v.
37 results on '"Kalarus, Zbigniew"'

1. Adherence to the “Atrial fibrillation Better Care” (ABC) pathway in patients with atrial fibrillation and cancer: A report from the ESC-EHRA EURObservational Research Programme in atrial fibrillation (EORP-AF) General Long-Term Registry

Author

Boriani Chair, G., Lip, G.Y.H., Tavazzi, L., Maggioni, A.P., Dan, GA., Potpara, T., Nabauer, M., Marin, F., Kalarus, Z., Fauchier, L., Goda, A., Mairesse, G., Shalganov, T., Antoniades, L., Taborsky, M., Riahi, S., Muda, P., Bolao, I. García, Piot, O., Etsadashvili, K., Simantirakis, EN., Haim, M., Azhari, A., Najafian, J., Santini, M., Mirrakhimov, E., Kulzida, K., Erglis, A., Poposka, L., Burg, MR., Crijns, H., Erküner, Ö., Atar, D., Lenarczyk, R., Oliveira, M. Martins, Shah, D., Serdechnaya, E., Dan, G-A., Diker, E., Lane, D., Vitolo, Marco, Proietti, Marco, Malavasi, Vincenzo L., Bonini, Niccolo’, Romiti, Giulio Francesco, Imberti, Jacopo F., Fauchier, Laurent, Marin, Francisco, Nabauer, Michael, Potpara, Tatjana S., Dan, Gheorghe-Andrei, Kalarus, Zbigniew, Maggioni, Aldo Pietro, Lane, Deirdre A., Lip, Gregory Y H, and Boriani, Giuseppe

Published
2022
Full Text
View/download PDF

2. Cardiac troponins and adverse outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EORP atrial fibrillation general long-term registry

Author

Boriani, G., Lip, G.Y.H., Tavazzi, L., Maggioni, A.P., Dan, G-A., Potpara, T., Nabauer, M., Marin, F., Kalarus, Z., Fauchier, L., Goda, A., Mairesse, G., Shalganov, T., Antoniades, L., Taborsky, M., Riahi, S., Muda, P., García Bolao, I., Piot, O., Etsadashvili, K., Haim, M., Azhari, A., Najafian, J., Santini, M., Mirrakhimov, E., Kulzida, K., Erglis, A., Poposka, L., Burg, M.R., Crijns, H., Erküner, Ö., Atar, D., Lenarczyk, R., Martins Oliveira, M., Shah, D., Serdechnaya, E., Diker, E., Zëra, E., Ekmekçiu, U., Paparisto, V., Tase, M., Gjergo, H., Dragoti, J., Ciutea, M., Ahadi, N., el Husseini, Z., Raepers, M., Leroy, J., Haushan, P., Jourdan, A., Lepiece, C., Desteghe, L., Vijgen, J., Koopman, P., Van Genechten, G., Heidbuchel, H., Boussy, T., De Coninck, M., Van Eeckhoutte, H., Bouckaert, N., Friart, A., Boreux, J., Arend, C., Evrard, P., Stefan, L., Hoffer, E., Herzet, J., Massoz, M., Celentano, C., Sprynger, M., Pierard, L., Melon, P., Van Hauwaert, B., Kuppens, C., Faes, D., Van Lier, D., Van Dorpe, A., Gerardy, A., Deceuninck, O., Xhaet, O., Dormal, F., Ballant, E., Blommaert, D., Yakova, D., Hristov, M., Yncheva, T., Stancheva, N., Tisheva, S., Tokmakova, M., Nikolov, F., Gencheva, D., Kunev, B., Stoyanov, M., Marchov, D., Gelev, V., Traykov, V., Kisheva, A., Tsvyatkov, H., Shtereva, R., Bakalska-Georgieva, S., Slavcheva, S., Yotov, Y., Kubíčková, M., Marni Joensen, A., Gammelmark, A., Hvilsted Rasmussen, L., Dinesen, P., Krogh Venø, S., Sorensen, B., Korsgaard, A., Andersen, K., Fragtrup Hellum, C., Svenningsen, A., Nyvad, O., Wiggers, P., May, O., Aarup, A., Graversen, B., Jensen, L., Andersen, M., Svejgaard, M., Vester, S., Hansen, S., Lynggaard, V., Ciudad, M., Vettus, R., Maestre, A., Castaño, S., Cheggour, S., Poulard, J., Mouquet, V., Leparrée, S., Bouet, J., Taieb, J., Doucy, A., Duquenne, H., Furber, A., Dupuis, J., Rautureau, J., Font, M., Damiano, P., Lacrimini, M., Abalea, J., Boismal, S., Menez, T., Mansourati, J., Range, G., Gorka, H., Laure, C., Vassalière, C., Elbaz, N., Lellouche, N., Djouadi, K., Roubille, F., Dietz, D., Davy, J., Granier, M., Winum, P., Leperchois-Jacquey, C., Kassim, H., Marijon, E., Le Heuzey, J., Fedida, J., Maupain, C., Himbert, C., Gandjbakhch, E., Hidden-Lucet, F., Duthoit, G., Badenco, N., Chastre, T., Waintraub, X., Oudihat, M., Lacoste, J., Stephan, C., Bader, H., Delarche, N., Giry, L., Arnaud, D., Lopez, C., Boury, F., Brunello, I., Lefèvre, M., Mingam, R., Haissaguerre, M., Le Bidan, M., Pavin, D., Le Moal, V., Leclercq, C., Beitar, T., Martel, I., Schmid, A., Sadki, N., Romeyer-Bouchard, C., Da Costa, A., Arnault, I., Boyer, M., Piat, C., Lozance, N., Nastevska, S., Doneva, A., Fortomaroska Milevska, B., Sheshoski, B., Petroska, K., Taneska, N., Bakrecheski, N., Lazarovska, K., Jovevska, S., Ristovski, V., Antovski, A., Lazarova, E., Kotlar, I., Taleski, J., Kedev, S., Zlatanovik, N., Jordanova, S., Bajraktarova Proseva, T., Doncovska, S., Maisuradze, D., Esakia, A., Sagirashvili, E., Lartsuliani, K., Natelashvili, N., Gumberidze, N., Gvenetadze, R., Gotonelia, N., Kuridze, N., Papiashvili, G., Menabde, I., Glöggler, S., Napp, A., Lebherz, C., Romero, H., Schmitz, K., Berger, M., Zink, M., Köster, S., Sachse, J., Vonderhagen, E., Soiron, G., Mischke, K., Reith, R., Schneider, M., Rieker, W., Boscher, D., Taschareck, A., Beer, A., Oster, D., Ritter, O., Adamczewski, J., Walter, S., Frommhold, A., Luckner, E., Richter, J., Schellner, M., Landgraf, S., Bartholome, S., Naumann, R., Schoeler, J., Westermeier, D., William, F., Wilhelm, K., Maerkl, M., Oekinghaus, R., Denart, M., Kriete, M., Tebbe, U., Scheibner, T., Gruber, M., Gerlach, A., Beckendorf, C., Anneken, L., Arnold, M., Lengerer, S., Bal, Z., Uecker, C., Förtsch, H., Fechner, S., Mages, V., Martens, E., Methe, H., Schmidt, T., Schaeffer, B., Hoffmann, B., Moser, J., Heitmann, K., Willems, S., Klaus, C., Lange, I., Durak, M., Esen, E., Mibach, F., Mibach, H., Utech, A., Gabelmann, M., Stumm, R., Ländle, V., Gartner, C., Goerg, C., Kaul, N., Messer, S., Burkhardt, D., Sander, C., Orthen, R., Kaes, S., Baumer, A., Dodos, F., Barth, A., Schaeffer, G., Gaertner, J., Winkler, J., Fahrig, A., Aring, J., Wenzel, I., Steiner, S., Kliesch, A., Kratz, E., Winter, K., Schneider, P., Haag, A., Mutscher, I., Bosch, R., Taggeselle, J., Meixner, S., Schnabel, A., Shamalla, A., Hötz, H., Korinth, A., Rheinert, C., Mehltretter, G., Schön, B., Schön, N., Starflinger, A., Englmann, E., Baytok, G., Laschinger, T., Ritscher, G., Gerth, A., Dechering, D., Eckardt, L., Kuhlmann, M., Proskynitopoulos, N., Brunn, J., Foth, K., Axthelm, C., Hohensee, H., Eberhard, K., Turbanisch, S., Hassler, N., Koestler, A., Stenzel, G., Kschiwan, D., Schwefer, M., Neiner, S., Hettwer, S., Haeussler-Schuchardt, M., Degenhardt, R., Sennhenn, S., Brendel, M., Stoehr, A., Widjaja, W., Loehndorf, S., Logemann, A., Hoskamp, J., Grundt, J., Block, M., Ulrych, R., Reithmeier, A., Panagopoulos, V., Martignani, C., Bernucci, D., Fantecchi, E., Diemberger, I., Ziacchi, M., Biffi, M., Cimaglia, P., Frisoni, J., Giannini, I., Boni, S., Fumagalli, S., Pupo, S., Di Chiara, A., Mirone, P., Pesce, F., Zoccali, C., Malavasi, V.L., Mussagaliyeva, A., Ahyt, B., Salihova, Z., Koshum-Bayeva, K., Kerimkulova, A., Bairamukova, A., Lurina, B., Zuzans, R., Jegere, S., Mintale, I., Kupics, K., Jubele, K., Kalejs, O., Vanhear, K., Burg, M., Cachia, M., Abela, E., Warwicker, S., Tabone, T., Xuereb, R., Asanovic, D., Drakalovic, D., Vukmirovic, M., Pavlovic, N., Music, L., Bulatovic, N., Boskovic, A., Uiterwaal, H., Bijsterveld, N., De Groot, J., Neefs, J., van den Berg, N., Piersma, F., Wilde, A., Hagens, V., Van Es, J., Van Opstal, J., Van Rennes, B., Verheij, H., Breukers, W., Tjeerdsma, G., Nijmeijer, R., Wegink, D., Binnema, R., Said, S., Philippens, S., van Doorn, W., Szili-Torok, T., Bhagwandien, R., Janse, P., Muskens, A., van Eck, M., Gevers, R., van der Ven, N., Duygun, A., Rahel, B., Meeder, J., Vold, A., Holst Hansen, C., Engset, I., Dyduch-Fejklowicz, B., Koba, E., Cichocka, M., Sokal, A., Kubicius, A., Pruchniewicz, E., Kowalik-Sztylc, A., Czapla, W., Mróz, I., Kozlowski, M., Pawlowski, T., Tendera, M., Winiarska-Filipek, A., Fidyk, A., Slowikowski, A., Haberka, M., Lachor-Broda, M., Biedron, M., Gasior, Z., Kołodziej, M., Janion, M., Gorczyca-Michta, I., Wozakowska-Kaplon, B., Stasiak, M., Jakubowski, P., Ciurus, T., Drozdz, J., Simiera, M., Zajac, P., Wcislo, T., Zycinski, P., Kasprzak, J., Olejnik, A., Harc-Dyl, E., Miarka, J., Pasieka, M., Ziemińska-Łuć, M., Bujak, W., Śliwiński, A., Grech, A., Morka, J., Petrykowska, K., Prasał, M., Hordyński, G., Feusette, P., Lipski, P., Wester, A., Streb, W., Romanek, J., Woźniak, P., Chlebuś, M., Szafarz, P., Stanik, W., Zakrzewski, M., Kaźmierczak, J., Przybylska, A., Skorek, E., Błaszczyk, H., Stępień, M., Szabowski, S., Krysiak, W., Szymańska, M., Karasiński, J., Blicharz, J., Skura, M., Hałas, K., Michalczyk, L., Orski, Z., Krzyżanowski, K., Skrobowski, A., Zieliński, L., Tomaszewska-Kiecana, M., Dłużniewski, M., Kiliszek, M., Peller, M., Budnik, M., Balsam, P., Opolski, G., Tymińska, A., Ozierański, K., Wancerz, A., Borowiec, A., Majos, E., Dabrowski, R., Szwed, H., Musialik-Lydka, A., Leopold-Jadczyk, A., Jedrzejczyk-Patej, E., Koziel, M., Mazurek, M., Krzemien-Wolska, K., Starosta, P., Nowalany-Kozielska, E., Orzechowska, A., Szpot, M., Staszel, M., Almeida, S., Pereira, H., Brandão Alves, L., Miranda, R., Ribeiro, L., Costa, F., Morgado, F., Carmo, P., Galvao Santos, P., Bernardo, R., Adragão, P., Ferreira da Silva, G., Peres, M., Alves, M., Leal, M., Cordeiro, A., Magalhães, P., Fontes, P., Leão, S., Delgado, A., Costa, A., Marmelo, B., Rodrigues, B., Moreira, D., Santos, J., Santos, L., Terchet, A., Darabantiu, D., Mercea, S., Turcin Halka, V., Pop Moldovan, A., Gabor, A., Doka, B., Catanescu, G., Rus, H., Oboroceanu, L., Bobescu, E., Popescu, R., Dan, A., Buzea, A., Daha, I., Dan, G., Neuhoff, I., Baluta, M., Ploesteanu, R., Dumitrache, N., Vintila, M., Daraban, A., Japie, C., Badila, E., Tewelde, H., Hostiuc, M., Frunza, S., Tintea, E., Bartos, D., Ciobanu, A., Popescu, I., Toma, N., Gherghinescu, C., Cretu, D., Patrascu, N., Stoicescu, C., Udroiu, C., Bicescu, G., Vintila, V., Vinereanu, D., Cinteza, M., Rimbas, R., Grecu, M., Cozma, A., Boros, F., Ille, M., Tica, O., Tor, R., Corina, A., Jeewooth, A., Maria, B., Georgiana, C., Natalia, C., Alin, D., Dinu-Andrei, D., Livia, M., Daniela, R., Larisa, R., Umaar, S., Tamara, T., Ioachim Popescu, M., Nistor, D., Sus, I., Coborosanu, O., Alina-Ramona, N., Dan, R., Petrescu, L., Ionescu, G., Vacarescu, C., Goanta, E., Mangea, M., Ionac, A., Mornos, C., Cozma, D., Pescariu, S., Solodovnicova, E., Soldatova, I., Shutova, J., Tjuleneva, L., Zubova, T., Uskov, V., Obukhov, D., Rusanova, G., Isakova, N., Odinsova, S., Arhipova, T., Kazakevich, E., Zavyalova, O., Novikova, T., Riabaia, I., Zhigalov, S., Drozdova, E., Luchkina, I., Monogarova, Y., Hegya, D., Rodionova, L., Nevzorova, V., Lusanova, O., Arandjelovic, A., Toncev, D., Vukmirovic, L., Radisavljevic, M., Milanov, M., Sekularac, N., Zdravkovic, M., Hinic, S., Dimkovic, S., Acimovic, T., Saric, J., Radovanovic, S., Kocijancic, A., Obrenovic-Kircanski, B., Kalimanovska Ostric, D., Simic, D., Jovanovic, I., Petrovic, I., Polovina, M., Vukicevic, M., Tomasevic, M., Mujovic, N., Radivojevic, N., Petrovic, O., Aleksandric, S., Kovacevic, V., Mijatovic, Z., Ivanovic, B., Tesic, M., Ristic, A., Vujisic-Tesic, B., Nedeljkovic, M., Karadzic, A., Uscumlic, A., Prodanovic, M., Zlatar, M., Asanin, M., Bisenic, B., Vasic, V., Popovic, Z., Djikic, D., Sipic, M., Peric, V., Dejanovic, B., Milosevic, N., Backovic, S., Stevanovic, A., Andric, A., Pencic, B., Pavlovic-Kleut, M., Celic, V., Pavlovic, M., Petrovic, M., Vuleta, M., Petrovic, N., Simovic, S., Savovic, Z., Milanov, S., Davidovic, G., Iric-Cupic, V., Djordjevic, D., Damjanovic, M., Zdravkovic, S., Topic, V., Stanojevic, D., Randjelovic, M., Jankovic-Tomasevic, R., Atanaskovic, V., Antic, S., Simonovic, D., Stojanovic, M., Stojanovic, S., Mitic, V., Ilic, V., Petrovic, D., Deljanin Ilic, M., Ilic, S., Stoickov, V., Markovic, S., Mijatovic, A., Tanasic, D., Radakovic, G., Peranovic, J., Panic-Jelic, N., Vujadinovic, O., Pajic, P., Bekic, S., Kovacevic, S., García Fernandez, A., Perez Cabeza, A., Anguita, M., Tercedor Sanchez, L., Mau, E., Loayssa, J., Ayarra, M., Carpintero, M., Roldán Rabadan, I., Gil Ortega, M., Tello Montoliu, A., Orenes Piñero, E., Manzano Fernández, S., Marín, F., Romero Aniorte, A., Veliz Martínez, A., Quintana Giner, M., Ballesteros, G., Palacio, M., Alcalde, O., García-Bolao, I., Bertomeu Gonzalez, V., Otero-Raviña, F., García Seara, J., Gonzalez Juanatey, J., Dayal, N., Maziarski, P., Gentil-Baron, P., Koç, M., Onrat, E., Dural, I.E., Yilmaz, K., Özin, B., Tan Kurklu, S., Atmaca, Y., Canpolat, U., Tokgozoglu, L., Dolu, A.K., Demirtas, B., Sahin, D., Ozcan Celebi, O., Gagirci, G., Turk, U.O., Ari, H., Polat, N., Toprak, N., Sucu, M., Akin Serdar, O., Taha Alper, A., Kepez, A., Yuksel, Y., Uzunselvi, A., Yuksel, S., Sahin, M., Kayapinar, O., Ozcan, T., Kaya, H., Yilmaz, M.B., Kutlu, M., Demir, M., Gibbs, C., Kaminskiene, S., Bryce, M., Skinner, A., Belcher, G., Hunt, J., Stancombe, L., Holbrook, B., Peters, C., Tettersell, S., Shantsila, A., Lane, D., Senoo, K., Proietti, M., Russell, K., Domingos, P., Hussain, S., Partridge, J., Haynes, R., Bahadur, S., Brown, R., McMahon, S., McDonald, J., Balachandran, K., Singh, R., Garg, S., Desai, H., Davies, K., Goddard, W., Galasko, G., Rahman, I., Chua, Y., Payne, O., Preston, S., Brennan, O., Pedley, L., Whiteside, C., Dickinson, C., Brown, J., Jones, K., Benham, L., Brady, R., Buchanan, L., Ashton, A., Crowther, H., Fairlamb, H., Thornthwaite, S., Relph, C., McSkeane, A., Poultney, U., Kelsall, N., Rice, P., Wilson, T., Wrigley, M., Kaba, R., Patel, T., Young, E., Law, J., Runnett, C., Thomas, H., McKie, H., Fuller, J., Pick, S., Sharp, A., Hunt, A., Thorpe, K., Hardman, C., Cusack, E., Adams, L., Hough, M., Keenan, S., Bowring, A., Watts, J., Zaman, J., Goffin, K., Nutt, H., Beerachee, Y., Featherstone, J., Mills, C., Pearson, J., Stephenson, L., Grant, S., Wilson, A., Hawksworth, C., Alam, I., Robinson, M., Ryan, S., Egdell, R., Gibson, E., Holland, M., Leonard, D., Mishra, B., Ahmad, S., Randall, H., Hill, J., Reid, L., George, M., McKinley, S., Brockway, L., Milligan, W., Sobolewska, J., Muir, J., Tuckis, L., Winstanley, L., Jacob, P., Kaye, S., Morby, L., Jan, A., Sewell, T., Boos, C., Wadams, B., Cope, C., Jefferey, P., Andrews, N., Getty, A., Suttling, A., Turner, C., Hudson, K., Austin, R., Howe, S., Iqbal, R., Gandhi, N., Brophy, K., Mirza, P., Willard, E., Collins, S., Ndlovu, N., Subkovas, E., Karthikeyan, V., Waggett, L., Wood, A., Bolger, A., Stockport, J., Evans, L., Harman, E., Starling, J., Williams, L., Saul, V., Sinha, M., Bell, L., Tudgay, S., Kemp, S., Frost, L., Ingram, T., Loughlin, A., Adams, C., Adams, M., Hurford, F., Owen, C., Miller, C., Donaldson, D., Tivenan, H., Button, H., Nasser, A., Jhagra, O., Stidolph, B., Brown, C., Livingstone, C., Duffy, M., Madgwick, P., Roberts, P., Greenwood, E., Fletcher, L., Beveridge, M., Earles, S., McKenzie, D., Beacock, D., Dayer, M., Seddon, M., Greenwell, D., Luxton, F., Venn, F., Mills, H., Rewbury, J., James, K., Roberts, K., Tonks, L., Felmeden, D., Taggu, W., Summerhayes, A., Hughes, D., Sutton, J., Felmeden, L., Khan, M., Walker, E., Norris, L., O'Donohoe, L., Mozid, A., Dymond, H., Lloyd-Jones, H., Saunders, G., Simmons, D., Coles, D., Cotterill, D., Beech, S., Kidd, S., Wrigley, B., Petkar, S., Smallwood, A., Jones, R., Radford, E., Milgate, S., Metherell, S., Cottam, V., Buckley, C., Broadley, A., Wood, D., Allison, J., Rennie, K., Balian, L., Howard, L., Pippard, L., Board, S., Pitt-Kerby, T., Vitolo, Marco, Malavasi, Vincenzo L., Proietti, Marco, Diemberger, Igor, Fauchier, Laurent, Marin, Francisco, Nabauer, Michael, Potpara, Tatjana S., Dan, Gheorghe-Andrei, Kalarus, Zbigniew, Tavazzi, Luigi, Maggioni, Aldo Pietro, Lane, Deirdre A., Lip, Gregory Y.H., and Boriani, Giuseppe

Published
2022
Full Text
View/download PDF

5. Predictors of proarrhythmic effect in heart failure patients after 9-week hybrid comprehensive telerehabilitation and their influence on cardiovascular mortality in long-term follow-up: Subanalysis of the TELEREH-HF randomized clinical trial.

Author

Piotrowicz, Ewa, Orzechowski, Piotr, Kowalik, Ilona, Zaręba, Wojciech, Pencina, Michael, Komar, Ewa, Opolski, Grzegorz, Banach, Maciej, Pluta, Sławomir, Główczyńska, Renata, Szalewska, Dominika, Kalarus, Zbigniew, Irzmański, Robert, and Piotrowicz, Ryszard

Abstract

Background: Regular exercise training is beneficial in heart failure (HF) patients. However, its potential proarrhythmic effect is possible but has not been sufficiently investigated.Objective: To identify patients at risk for proarrhythmic effect after the 9-week of hybrid comprehensive telerehabilitation (HCTR) program vs the 9-week of usual care (UC) and to investigate its predictors and impact on cardiovascular mortality based on data from the TELEREH-HF RCT.Methods: Proarrhythmic effect, strictly defined on the basis of available standards was evaluated by comparing 24-h Holter ECG before and after 9-week of HCTR or UC of 773 HF patients (The New York Heart Association class I-III, left ventricular ejection fraction ≤40%).Results: The proarrhytmic effect was found in 78 (20.4%) and in 61 (15.6%) patients in the HCTR and UC group respectively, and the difference between groups was not statistically significant (p = 0.081). However, univariate analysis identified several statistically significant predictors of proarrhythmia in HCTR only vs the UC group. After a multivariate analysis ischaemic aetiology of HF (OR = 2.27, p = 0.008), peak oxygen consumption at baseline <14 ml/kg/min (OR = 2.03, p = 0.012) and level of N-terminal-pro B-type natriuretic peptide (NT-proBNP) in the first and the second tercile (OR = 1.85, p = 0.043) were identified to be independent predictors of proarrhytmic effect of exercise training among the HF patients in HCTR group only.Conslusions: Patients who underwent a 9-week HCTR were not at a higher risk of proarrhythmic effect after its completion compared to UC. However, predictors of proarrhythmia such as ischemic aetiology of HF, poor physical capacity, lower NT-proBNP level were discovered in the HCTR group only, yet it does not cause a significant risk of cardiovascular mortality including sudden cardiac death in long-term follow-up. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

6. Importance of complete revascularization in patients with acute myocardial infarction treated with percutaneous coronary intervention

Author

Kalarus, Zbigniew, Lenarczyk, Radoslaw, Kowalczyk, Jacek, Kowalski, Oskar, Gasior, Mariusz, Was, Tomasz, Zebik, Tadeusz, Krupa, Hubert, Chodor, Piotr, Polonski, Lech, and Zembala, Marian

Subjects
Heart attack -- Care and treatment, Transluminal angioplasty -- Patient outcomes, Transluminal angioplasty -- Research, Mortality -- Risk factors, Mortality -- Research, Hospital utilization -- Length of stay, Hospital utilization -- Research, Health
Published
2007

7. The first successful implantation of an intravenous AAIR pacemaker into autologous extracardiac lateral tunnel Fontan in the child.

Author

Konieczny, Aleksandra, Jędrzejczyk-Patej, Ewa, Kozielski, Jonasz, Kowalska, Wiktoria, Bugajski, Maciej, Litwin, Linda, Kalarus, Zbigniew, Średniawa, Beata, and Kowalski, Oskar

Abstract

Patients with a single ventricle have complex anatomy that requires staged palliation which is usually the Fontan procedure. This procedure has undergone a lot of modifications to improve hemodynamics. Despite these efforts, sinus node dysfunction (SND) and bradyarrythmias are still common complications after Fontan operation, therefore there is a need of pacemakers implantation. Unfortunately, the most frequent technique of creating Fontan cannale - the extracardiac lateral tunnel makes the transvenous access to the atrium difficult or impossible to achieve. We report a case of successful implantation of an endocardial atrial lead for SND in patient with an extracardiac autologous Fontan tunnel. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

8. Prognostic value of collagen turnover biomarkers in cardiac resynchronization therapy: A subanalysis of the TRUST CRT randomized trial population.

Author

Sokal, Adam, Lenarczyk, Radoslaw, Kowalski, Oskar, Mitrega, Katarzyna, Pluta, Slawomir, Stabryla-Deska, Joanna, Streb, Witold, Urbanik, Zofia, Krzeminski, Tadeusz F., and Kalarus, Zbigniew

Abstract

Background: A substantial proportion of patients do not respond to cardiac resynchronization therapy (CRT). Various echocardiographic and biochemical markers including collagen turnover biomarkers were suggested to predict CRT results. However, pathological significance of collagen turnover biomarkers in CRT remains controversial.Objective: The aim of the present study was to evaluate the relationship between levels of collagen turnover biomarkers (amino-terminal propeptide of procollagen type I and amino-terminal propeptide of procollagen type III [PIIINP]), N-terminal of the prohormone brain natriuretic peptide (NT-proBNP), high-sensitivity C-reactive protein, and matrix metalloproteinases (metalloproteinase-2 and metalloproteinase-9) and echocardiographic response to CRT and clinical outcomes.Methods: The study population consisted of patients enrolled in the Triple Site Versus Standard Cardiac Resynchronization Therapy trial. Blood samples were obtained before implantation of a CRT with defibrillator. The levels of PIIINP, amino-terminal propeptide of procollagen type I, metalloproteinase-2, and metalloproteinase-9 were determined using commercially available ELISA kits. High-sensitivity C-reactive protein and NT-proBNP levels were determined in a standard way.Results: Samples were collected from 74 of 100 enrolled patients. The multivariate logistic regression analysis demonstrated that low PIIINP levels (odds ratio [OR] 3.56; 95% confidence interval [CI] 1.23-10.24; P = .017) and baseline ejection fraction (OR 2.14; 95% CI 1.11-4.11; P = .02) were favorably associated with echocardiographic response. PIIINP and NT-proBNP levels appeared to be independent predictors of all-cause mortality (PIIINP: OR 3.11; 95% CI 1.21-7.89; P = .033; NT-proBNP: OR 2.05; 95% CI 1.11-4.96; P = .039) and risk of major cardiac adverse event (PIIINP: OR 3.56; 95% CI 1.53-9.15; P = .007; NT-proBNP: OR 4.51; 95% CI 1.75-11.6; P = .001). PIIINP levels showed significant additive value in predicting mortality as compared with NT-proBNP levels, but they were not superior to ejection fraction in predicting response. Survival analysis with cutoff values identified by receiver operating characteristic analysis confirmed a significant benefit associated with low baseline PIIINP levels.Conclusion: Low PIIINP levels are associated with favorable echocardiographic response and long-term survival in CRT recipients. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

9. B-PO03-043 LONG TERM EFFECTS OF CARDIAC NEUROMODULATION THERAPY ON SYSTOLIC BLOOD PRESSURE IN CONTROL PATIENTS AFTER CROSS OVER TO THERAPY.

Author

Kalarus, Zbigniew, Merkely, Bela, Grabowski, Marcin, Neuzil, Petr, Marinskis, Germanas, Mitkowski, Przemyslaw P., Erglis, Andrejs, Kazmierczak, Jaroslaw, Pluta, Slawomir, Geller, Laszlo, Osztheimer, Istvan, Lidia Chmielewska-Michalak, Libor Dujka, Ieva Anasberga, Agnieska Kolodzinska, Jurate Barysiene, Filip Malek, Milosz Stepien, Diana Paskudzka, and Sokal, Adam

Published
2021
Full Text
View/download PDF

11. Transcatheter Closure of Postinfarction Ventricular Septal Defects Using Amplatzer Devices.

Author

Bialkowski, Jacek, Szkutnik, Malgorzata, Kusa, Jacek, Kalarus, Zbigniew, Gasior, Mariusz, Przybylski, Roman, Banaszak, Pawel, and Zembala, Marian

Subjects
VENTRICULAR septal defects, CARDIAC catheterization, MYOCARDIAL infarction, CORONARY disease, HEART diseases
Abstract

Copyright of Revista Española de Cardiología (18855857) is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2007
Full Text
View/download PDF

13. TWO YEAR SAFETY AND EFFICACY OF CARDIAC NEUROMODULATION THERAPY IN HYPERTENSIVE PATIENTS INDICATED FOR A PACEMAKER.

Author

Kalarus, Zbigniew, Bela, Merkely P., Neuzil, Petr, Mitkowski, Przemyslaw, Erglis, Andrejs, Grawobski, Marcin, Marinskis, Germanas, Kazmierczak, Jaroslaw, Pluta, Slawomir, Geller, Laszlo, Osztheimer, Istvan, Malek, Filip, Dujka, Libor, Chmielewska-Michalak, Lidia, Kolodzinska, Agnieska, Anasberga, Ieva, Barysiene, Jurate, Paskusdzka, Diana, Stepien, Milosz, and Sokal, Adam

Subjects
*DRUG efficacy, *HYPERTENSION, *CARDIAC patients
Published
2021
Full Text
View/download PDF

14. Left ventricular twist abnormalities in patients with left ventricular non-compaction. A cardiovascular magnetic resonance study.

Author

Miszalski-Jamka, Karol, Taylor, Michael, Glowacki, Jan, Hor, Kan N., Miszalski-Jamka, Tomasz, Rycaj, Jaroslaw, Adamczyk, Tomasz, Kwiecinski, Radoslaw, Klys, Jan, Williams, Kathleen I., Huang, Victoria M., Kluczewska, Ewa, Kalarus, Zbigniew, and Mazur, Wojciech

Subjects
LEFT heart ventricle, CARDIOVASCULAR system, MAGNETIC resonance imaging
Abstract

An abstract of the conference paper "Left ventricular twist abnormalities in patients with left ventricular non-compaction. A cardiovascular magnetic resonance study," by Karol Miszalski-Jamka and colleagues is presented.

Published
2012
Full Text
View/download PDF

16. Adherence to the "Atrial fibrillation Better Care" (ABC) pathway in patients with atrial fibrillation and cancer: A report from the ESC-EHRA EURObservational Research Programme in atrial fibrillation (EORP-AF) General Long-Term Registry.

Author

Vitolo, Marco, Proietti, Marco, Malavasi, Vincenzo L., Bonini, Niccolo', Romiti, Giulio Francesco, Imberti, Jacopo F., Fauchier, Laurent, Marin, Francisco, Nabauer, Michael, Potpara, Tatjana S., Dan, Gheorghe-Andrei, Kalarus, Zbigniew, Maggioni, Aldo Pietro, Lane, Deirdre A., Lip, Gregory Y H, and Boriani, Giuseppe

Subjects
*ATRIAL fibrillation, *MAJOR adverse cardiovascular events
Abstract

• Appropriate management of AF patients with cancer in real-world clinical practice is challenging. • In this EORP-AF study, we analyzed a cohort of AF patients with prior or active cancer. • A structured approach based on the "Atrial fibrillation Better Care" (ABC) Pathway is still suboptimal. • Adherence to the "C" criterion (i.e. management of comorbidities) was more critical, being specifically lower in cancer patients. • Adherence to the ABC pathway was independently associated with a lower risk outcomes. Implementation of the Atrial fibrillation Better Care (ABC) pathway is recommended by guidelines on atrial fibrillation (AF), but the impact of adherence to ABC pathway in patients with cancer is unknown. To investigate the adherence to ABC pathway and its impact on adverse outcomes in AF patients with cancer. Patients enrolled in the EORP-AF General Long-Term Registry were analyzed according to (i) No Cancer; and (ii) Prior or active cancer and stratified in relation to adherence to the ABC pathway. The composite Net Clinical Outcome (NCO) of all-cause death, major adverse cardiovascular events and major bleeding was the primary endpoint. Among 6550 patients (median age 69 years, females 40.1%), 6005 (91.7%) had no cancer, while 545 (8.3%) had a diagnosis of active or prior cancer at baseline, with the proportions of full adherence to ABC pathway of 30.6% and 25.7%, respectively. Adherence to the ABC pathway was associated with a significantly lower occurrence of the primary outcome vs. non-adherence, both in 'no cancer' and 'cancer' patients [adjusted Hazard Ratio (aHR) 0.78, 95% confidence interval (CI): 0.66–0.92 and aHR 0.59, 95% CI 0.37–0.96, respectively]. Adherence to a higher number of ABC criteria was associated with a lower risk of the primary outcome, being lowest when 3 ABC criteria were fulfilled (no cancer: aHR 0.54, 95%CI: 0.36–0.81; with cancer: aHR 0.32, 95% CI 0.13–0.78). In AF patients with cancer enrolled in the EORP-AF General Long-Term Registry, adherence to ABC pathway was sub-optimal. Full adherence to ABC-pathway was associated with a lower risk of adverse events [Display omitted] Adherence to the "Atrial fibrillation Better Care" (ABC) pathway in patients with atrial fibrillation and cancer and its impact on clinical outcomes. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

17. Cardiac troponins and adverse outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EORP atrial fibrillation general long-term registry.

Author

Vitolo, Marco, Malavasi, Vincenzo L., Proietti, Marco, Diemberger, Igor, Fauchier, Laurent, Marin, Francisco, Nabauer, Michael, Potpara, Tatjana S., Dan, Gheorghe-Andrei, Kalarus, Zbigniew, Tavazzi, Luigi, Maggioni, Aldo Pietro, Lane, Deirdre A., Lip, Gregory Y.H., and Boriani, Giuseppe

Subjects
*ATRIAL fibrillation, *MAJOR adverse cardiovascular events, *ACUTE coronary syndrome, *CORONARY artery disease
Abstract

• Elevated levels of cTn were independently associated with an increased risk adverse cardiovascular events, even in AF patients without coronary artery disease. • A reasonable application of cardiac troponins in AF patients may support clinical-decision making and also integrate outcome prediction and risk stratification. • Future studies are needed to investigate the mechanisms of cardiac troponins elevation in AF patients independently of cardiac ischemia. Cardiac troponins (cTn) have been reported to be predictors for adverse outcomes in atrial fibrillation (AF), patients, but their actual use is still unclear. To assess the factors associated with cTn testing in routine practice and evaluate the association with outcomes. Patients enrolled in the ESC-EHRA EORP-AF General Long-Term Registry were stratified into 3 groups according to cTn levels as (i) cTn not tested, (ii) cTn in range (≤99th percentile), (iii) cTn elevated (>99th percentile). The composite outcome of any thromboembolism /any acute coronary syndrome/cardiovascular (CV) death, defined as Major Adverse Cardiovascular Events (MACE) and all-cause death were the main endpoints. Among 10 445 AF patients (median age 71 years, 40.3% females) cTn were tested in 2834 (27.1%). cTn was elevated in 904/2834 (31.9%) and in-range in 1930/2834 (68.1%) patients. Female sex, in-hospital enrollment, first-detected AF, CV risk factors, history of coronary artery disease, and atypical AF symptoms were independently associated with cTn testing. Elevated cTn were independently associated with a higher risk for MACE (Model 1, hazard ratio [HR] 1.74, 95% confidence interval [CI] 1.40–2.16, Model 2, HR 1.62, 95% CI 1.28–2.05; Model 3 HR 1.76, 95% CI 1.37–2.26) and all-cause death (Model 1, HR 1.45, 95% CI 1.21–1.74; Model 2, HR 1.36, 95% CI 1.12–1.66; Model 3, HR 1.38, 95% CI 1.12–1.71). Elevated cTn levels were associated with an increased risk of all-cause mortality and adverse CV events. Clinical factors that might enhance the need to rule out CAD were associated with cTn testing. Cardiac troponins and adverse outcomes in patients with atrial fibrillation Legend: AF= atrial fibrillation; CAD= coronary artery disease; cTn= cardiac troponins; MACE= major adverse cardiovascular events [Display omitted]. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

19. TCT-401 Sex-Related Differences in Baseline Characteristic and Outcomes in Patients With Myocardial Infarction With Nonobstructive Coronary Arteries: Insight From Large-Scale Polish Registry.

Author

Milewski, Marek, Desperak, Aneta, Bujak, Marta, Gierlotka, Marek, Milewski, Krzysztof, Wita, Krystian, Kalarus, Zbigniew, Fluder, Joanna, Buszman, Paweł, Piegza, Jacek, Mamas, Mamas, Wojakowski, Wojciech, and Gasior, Pawel

Subjects
*MYOCARDIAL infarction, *CORONARY arteries, *TREATMENT effectiveness
Published
2023
Full Text
View/download PDF

20. TCT-38 Impact of Smoking on Outcomes in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention.

Author

Buszman, Paweł, Bujak, Marta, Desperak, Aneta, Gierlotka, Marek, Milewski, Krzysztof, Wita, Krystian, Kalarus, Zbigniew, Fluder, Joanna, Kazmierski, Maciej, Gasior, Mariusz, Wojakowski, Wojciech, and Gasior, Pawel

Subjects
*ST elevation myocardial infarction, *PERCUTANEOUS coronary intervention, *TREATMENT effectiveness, *SMOKING
Published
2022
Full Text
View/download PDF

21. Do we need to monitor the percentage of biventricular pacing day by day?

Author

Mazurek, Michał, Jędrzejczyk-Patej, Ewa, Lenarczyk, Radosław, Liberska, Agnieszka, Przybylska-Siedlecka, Katarzyna, Kozieł, Monika, Morawski, Stanisław, Podolecki, Tomasz, Kowalczyk, Jacek, Pruszkowska, Patrycja, Pluta, Sławomir, Sokal, Adam, Kowalski, Oskar, and Kalarus, Zbigniew

Subjects
*CARDIAC pacing, *DISEASE incidence, *DEFIBRILLATORS, *IMPLANTABLE cardioverter-defibrillators, *FOLLOW-up studies (Medicine), *HEART disease related mortality
Abstract

Background Incidence and clinical significance of transient, daily fluctuations of biventricular pacing percentage (CRT%) remain unknown. We assessed the value of daily remote monitoring in identifying prognostically critical burden of low CRT%. Methods and results Prospective, single-centre registry encompassed 304 consecutive heart failure patients with cardiac resynchronization therapy defibrillators (CRT-D). Patients with 24-h episodes of CRT% loss < 95% were assigned to quartiles depending on cumulative time spent in low CRT%: quartile 1 (1–8 days), 2 (9–20 days), 3 (21–60 days) and quartile 4 (> 60 days). During median follow-up of 35 months 51,826 transmissions were analysed, including 15,029 in 208 (68.4%) patients with episodes of low CRT%. Overall, mean CRT% ≥ 95% vs. < 95% resulted in a 4-fold lower mortality (17.3 vs. 68.2%; p < 0.001). Fifty-four percent of patients experienced episodes of CRT% loss, despite 85.6% having mean CRT% ≥ 95%. Mortality was lowest in quartile 1 (7.7%), while longer periods of CRT% loss resulted in significantly higher death rates (25.0 vs. 34.6 vs. 57.7%; quartiles 2–4 respectively, p < 0.001), despite mean CRT% still being ≥ 95% in quartiles 1–3. Cumulative low CRT% burden was the independent risk factor for death (HR 1.013; 95% CI 1.006–1.021; p < 0.001). Mortality rose by 1.3 and 49% with every additional day and quartile of CRT% loss, respectively. Conclusions Daily remote monitoring allows one to detect 24-h episodes of CRT% loss < 95% in over two-thirds of CRT-D recipients during median observation of 3 years. Cumulative low CRT% burden (in days) independently predicts mortality before mean CRT% drop. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

22. Randomized placebo controlled blinded study to assess valsartan efficacy in preventing left ventricle remodeling in patients with dual chamber pacemaker — Rationale and design of the trial.

Author

Tomasik, Andrzej, Jacheć, Wojciech, Wojciechowska, Celina, Kawecki, Damian, Białkowska, Beata, Romuk, Ewa, Gabrysiak, Artur, Birkner, Ewa, Kalarus, Zbigniew, and Nowalany-Kozielska, Ewa

Subjects
*RANDOMIZED controlled trials, *VALSARTAN, *DRUG design, *DRUG efficacy, *CARDIAC pacemakers, *MATRIX metalloproteinases, *HEART physiology, *LEFT heart ventricle, *LABORATORY dogs
Abstract

Background Dual chamber pacing is known to have detrimental effect on cardiac performance and heart failure occurring eventually is associated with increased mortality. Experimental studies of pacing in dogs have shown contractile dyssynchrony leading to diffuse alterations in extracellular matrix. In parallel, studies on experimental ischemia/reperfusion injury have shown efficacy of valsartan to inhibit activity of matrix metalloproteinase-9, to increase the activity of tissue inhibitor of matrix metalloproteinase-3 and preserve global contractility and left ventricle ejection fraction. Purpose To present rationale and design of randomized blinded trial aimed to assess whether 12 month long administration of valsartan will prevent left ventricle remodeling in patients with preserved left ventricle ejection fraction (LVEF ≥ 40%) and first implantation of dual chamber pacemaker. Methods A total of 100 eligible patients will be randomized into three parallel arms: placebo, valsartan 80 mg/daily and valsartan 160 mg/daily added to previously used drugs. The primary endpoint will be assessment of valsartan efficacy to prevent left ventricle remodeling during 12 month follow-up. We assess patients' functional capacity, blood plasma activity of matrix metalloproteinases and their tissue inhibitors, NT-proBNP, tumor necrosis factor alpha, and Troponin T. Left ventricle function and remodeling is assessed echocardiographically: M-mode, B-mode, tissue Doppler imaging. Conclusion If valsartan proves effective, it will be an attractive measure to improve long term prognosis in aging population and increasing number of pacemaker recipients. ClinicalTrials.org ( NCT01805804 ). [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

23. Mortality of patients with ST-segment elevation myocardial infarction and cardiogenic shock treated by PCI is correlated to the infarct-related artery – Results from the PL-ACS Registry

Author

Trzeciak, Przemysław, Gierlotka, Marek, Gąsior, Mariusz, Lekston, Andrzej, Wilczek, Krzysztof, Słonka, Grzegorz, Kalarus, Zbigniew, Zembala, Marian, Hudzik, Bartosz, and Poloński, Lech

Subjects
*MYOCARDIAL infarction treatment, *CARDIOGENIC shock, *HEART disease related mortality, *CORONARY heart disease risk factors, *ANGIOPLASTY, *CORONARY artery physiology, *THERAPEUTICS
Abstract

Abstract: Background: Mortality of patients with ST-segment elevation myocardial infarction (STEMI) with cardiogenic shock (CS) on admission remains high despite invasive treatment. The aim of this analysis was to assess the relationship between the infarct-related artery (IRA) and the early and 12-month outcomes of patients with STEMI and CS treated by percutaneous coronary intervention (PCI). Methods: Two thousand ninety patients with STEMI and CS registered in the prospective Polish Registry of Acute Coronary Syndromes from October 2003 to November 2009 were included. Results: The in-hospital mortality in the left main (LM), left anterior descending artery (LAD), circumflex artery (Cx), and right coronary artery (RCA) groups was 64.7%, 41.0%, 36.0%, and 30.8%, respectively, with p<0.0001. The 12-month mortality in the LM, LAD, Cx, and RCA groups was 77.7%, 58.2%, 55.1%, and 45.0%, respectively, with p<0.0001. After multivariate adjustment, LM as the IRA was significantly associated with higher 12-month mortality (hazard ratio=1.71, 95% confidence interval=1.28–2.27, p=0.0002). Conclusions: In-hospital and long-term mortality of patients with STEMI and CS treated by PCI are significantly correlated to the IRA, being highest for LM and lowest for RCA. [Copyright &y& Elsevier]

Published
2013
Full Text
View/download PDF

24. Effect of Type of Atrial Fibrillation on Prognosis in Acute Myocardial Infarction Treated Invasively

Author

Podolecki, Tomasz, Lenarczyk, Radosław, Kowalczyk, Jacek, Kurek, Tomasz, Boidol, Joanna, Chodor, Piotr, Swiatkowski, Andrzej, Sredniawa, Beata, Polonski, Lech, and Kalarus, Zbigniew

Subjects
*ATRIAL fibrillation, *MYOCARDIAL infarction, *MYOCARDIAL infarction treatment, *HEALTH outcome assessment, *FOLLOW-up studies (Medicine), *ARRHYTHMIA, *MEDICAL statistics, *PROGNOSIS
Abstract

To assess the incidence of atrial fibrillation (AF) and the clinical impact of AF types on outcomes in patients with acute myocardial infarction (AMI) treated invasively, we analyzed 2,980 consecutive patients with AMI admitted to our department from 2003 through 2008. Data collected by the insurer were screened to identify patients who died during the median follow-up of 41 months. AF was recognized in 282 patients (9.46%, AF group); the remaining 2,698 patients (90.54%) were free of this arrhythmia (control group). The AF group was divided into 3 subgroups: prehospital paroxysmal AF (n = 92, 3.09%), new-onset AF (n = 109, 3.66%), and permanent AF (n = 81, 2.72%). In-hospital and long-term mortalities were significantly higher (p <0.001 for the 2 comparisons) in the AF than in the control group (14.9% vs 5.3%, 37.2% vs 17.0%, respectively). Long-term mortality was significantly higher (p <0.001 for the 2 comparisons) in the new-onset AF (35.8%) and permanent AF (54.3%) groups than in the control group but did not differ significantly between the prehospital AF and control groups (21.7% vs 17.0%, p = NS). Considering types of arrhythmia separately, only permanent AF (hazard ratio 2.59) was an independent risk factor for death in the studied population. In conclusion, AF occurs in 1 of 10 patients with AMI treated invasively, with nearly equal distributions among prehospital, new-onset, and permanent forms. Although arrhythmia is a marker of worse short- and long-term outcomes, only permanent AF is an independent predictor for death in this population. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

25. A comparison of ST elevation versus non-ST elevation myocardial infarction outcomes in a large registry database: Are non-ST myocardial infarctions associated with worse long-term prognoses?

Author

Polonski, Lech, Gasior, Mariusz, Gierlotka, Marek, Osadnik, Tadeusz, Kalarus, Zbigniew, Trusz-Gluza, Maria, Zembala, Marian, Wilczek, Krzysztof, Lekston, Andrzej, Zdrojewski, Tomasz, and Tendera, Michal

Subjects
*ELECTROCARDIOGRAPHY, *MYOCARDIAL infarction, *COMPARATIVE studies, *TREATMENT effectiveness, *MEDICAL care, *MYOCARDIAL revascularization, *TRANSLUMINAL angioplasty, *PROGNOSIS
Abstract

Abstract: Background: Prognoses in STEMI and NSTEMI beyond one year from onset remain unclear. We aimed to compare the treatments and the two-year outcomes in patients with myocardial infarction (MI) enrolled at the Polish Registry of Acute Coronary Syndromes (PL-ACS). Methods: A total of 13,441 patients with MI (8250 with STEMI, and 5191 with NSTEMI) underwent medical care between October 2003 and June 2005 in the Silesia region (4.8 million inhabitants). The events analyzed were death, MI, stroke and percutaneous (PCI) or surgical (CABG) revascularization. Results: After two years, NSTEMI was associated with a higher incidence of death (hazard ratio (HR) of 1.09 (95% confidence interval (CI) 1.02–1.17, p<0.0001)); a higher incidence of reinfarction, stroke, CABG and a lower rate of PCI. Adjustments for baseline characteristics and treatment strategy (invasive vs. non-invasive) reversed the HR for mortality and eliminated the difference in MI and stroke. The adjusted HR for mortality was 0.76 (95% CI, 0.71–0.83, p<0.0001). STEMI and NSTEMI patients treated non-invasively were older and showed higher incidences of diabetes, obesity, pulmonary edema and cardiogenic shock than their invasively treated counterparts. Invasively treated patients received aspirin, beta-blockers, ACE inhibitors and statins more often during hospitalization and at discharge. Conclusions: The unadjusted long-term prognosis was worse in NSTEMI. After adjustment for the baseline characteristics and treatment strategy, the long-term prognosis was worse in STEMI. Patients with MI treated invasively showed more favorable clinical characteristics and received guideline-recommended therapy more often than patients who did not undergo invasive treatment. [Copyright &y& Elsevier]

Published
2011
Full Text
View/download PDF

26. Reperfusion by Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction Within 12 to 24 Hours of the Onset of Symptoms (from a Prospective National Observational Study [PL-ACS])

Author

Gierlotka, Marek, Gasior, Mariusz, Wilczek, Krzysztof, Hawranek, Michal, Szkodzinski, Janusz, Paczek, Piotr, Lekston, Andrzej, Kalarus, Zbigniew, Zembala, Marian, and Polonski, Lech

Subjects
*MYOCARDIAL infarction treatment, *SCIENTIFIC observation, *REPERFUSION injury, *CARDIOGENIC shock, *PULMONARY edema, *THROMBOLYTIC therapy
Abstract

The aim of the present study was to investigate whether reperfusion by primary percutaneous coronary intervention (PCI) improves 12-month survival in late presenters with ST-segment elevation myocardial infarction (STEMI). We analyzed 2,036 patients with STEMI presenting 12 to 24 hours from onset of symptoms, without cardiogenic shock or pulmonary edema and not reperfused by thrombolysis, of 23,517 patients with STEMI enrolled in the Polish Registry of Acute Coronary Syndromes from June 2005 to August 2006. An invasive approach was chosen in 910 (44.7%) of late presenters and 92% of them underwent reperfusion by PCI. Patients with an invasive approach had lower mortality after 12 months than patients with a conservative approach (9.3% vs 17.9%, p <0.0001). The benefit of an invasive approach was also observed after multivariate adjustment with a relative risk 0.73 for 12-month mortality (95% confidence interval 0.56 to 0.96) and in a subpopulation of patients selected by a propensity-score matching procedure with an adjusted relative risk 0.73 for 12-month mortality (0.58 to 0.99). In conclusion, almost 1/2 of late presenters with STEMI were considered eligible for reperfusion by primary PCI. These patients had a lower 12-month mortality rate than they would have had if they had been treated conservatively, which supports the idea of late reperfusion in STEMI. However, whether all late presenters with STEMI should be treated invasively remains unanswered. Nevertheless, until a randomized trial is undertaken, late presenters with STEMI could be considered for reperfusion by primary PCI. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

27. Comparison of Invasive and Non-Invasive Treatment Strategies in Older Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock (from the Polish Registry of Acute Coronary Syndromes - PL-ACS)

Author

Gasior, Mariusz, Slonka, Grzegorz, Wilczek, Krzysztof, Gierlotka, Marek, Ruzyllo, Witold, Zembala, Marian, Osadnik, Tadeusz, Dubiel, Jacek, Zdrojewski, Tomasz, Kalarus, Zbigniew, and Polonski, Lech

Subjects
*MYOCARDIAL infarction complications, *OLDER patients, *MYOCARDIAL infarction, *CARDIOGENIC shock, *HEART disease related mortality, *HOSPITAL care, *CLINICAL trials, *PATIENTS, *THERAPEUTICS
Abstract

Cardiogenic shock (CS) continues to be the most important factor affecting the mortality rate of patients with acute myocardial infarctions (AMIs). However, controversy regarding the optimal treatment of older patients with AMIs complicated by CS still exists. The aim of this study was to compare the results of invasive (coronary angiography during index hospitalization) and noninvasive treatment strategies in patients aged ≥75 years with AMIs complicated by CS, defined as systolic blood pressure <90 mm Hg or need for hemodynamic support and end-organ hypoperfusion. A multicenter Polish registry that included data on patients with acute coronary syndromes was examined to identify patients with AMIs treated from October 2003 to May 2007. A total of 97,531 patients with AMIs were hospitalized, and 5.5% of those patients (n = 5,390) had CS on admission, including 1,976 patients aged ≥75 years (509 treated invasively and 1,467 treated noninvasively). In-hospital mortality was 55.4% in patients treated invasively and 69.9% in patients treated noninvasively (p <0.0001). After 6 months, the mortality rate was 65.8% in the invasive group and 80.5% in the noninvasive group (p <0.0001). Propensity score analysis, in which 499 patients of each group were analyzed after being matched for demographic and clinical data, confirmed the early and long-term benefits of the invasive strategy. In conclusion, applying the invasive strategy to patients with AMIs complicated by CS reduced in-hospital and 6-month mortality in patients aged ≥75 years. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

28. Effect of Anemia in High-Risk Groups of Patients With Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention

Author

Kurek, Tomasz, Lenarczyk, Radosław, Kowalczyk, Jacek, Świątkowski, Andrzej, Kowalski, Oskar, Stabryła-Deska, Joanna, Honisz, Grzegorz, Lekston, Andrzej, Kalarus, Zbigniew, and Kukulski, Tomasz

Subjects
*ANEMIA, *ELECTROCARDIOGRAPHY, *MYOCARDIAL infarction, *THROMBOLYTIC therapy, *CORONARY heart disease treatment, *HEART disease risk factors, *COMPARATIVE studies, *PATIENTS
Abstract

The significance of anemia in patients with acute myocardial infarction (AMI) treated with percutaneous coronary intervention (PCI) remains controversial. The aim of the present study was to evaluate the effect of anemia on the short- and long-term prognosis of patients with AMI treated with PCI, including high-risk subgroups. The study group consisted of 1,497 consecutive patients with AMI treated in the acute phase with PCI. Anemia was defined using World Health Organization criteria (hemoglobin level <13 g/dl for men and <12 g/dl for women). The study population was divided into 2 major groups (patients with [n = 248, 16.6%] and without [n = 1,249, 83.4%] anemia) and 6 subgroups (diabetes mellitus, impaired renal function, age >70 years, left ventricular dysfunction, incomplete revascularization, and multivessel disease). A comparative analysis was performed between both groups within the whole population and within the particular subgroups. Significantly greater 30-day (13.2% vs 7.3%), 1-year (20.5% vs 11.3%), and total (24.1% vs 12.7%; all p <0.05) mortality rates were observed in the anemic group. Multivariate analysis identified anemia as an independent predictor of any-cause death in the whole population during the observation period (covariate-adjusted hazard ratio 1.46, 95% confidence interval 1.31 to 1.61, p <0.05). Anemia was significantly associated with excessive long-term mortality in the multivessel disease group (adjusted hazard ratio 1.54, 95% confidence interval 1.34 to 1.74) and in the incomplete revascularization group (hazard ratio 1.67, both p <0.05). In conclusion, anemia on admission in patients with AMI treated in the acute phase with PCI was independently associated with increasing short- and long-term mortality, especially in the subgroups with incomplete revascularization and multivessel disease. [Copyright &y& Elsevier]

Published
2010
Full Text
View/download PDF

29. Mid-term outcomes of triple-site vs. conventional cardiac resynchronization therapy: A preliminary study

Author

Lenarczyk, Radosław, Kowalski, Oskar, Kukulski, Tomasz, Pruszkowska-Skrzep, Patrycja, Sokal, Adam, Szulik, Mariola, Zielińska, Teresa, Kowalczyk, Jacek, Pluta, Sławomir, Średniawa, Beata, Musialik-Łydka, Agata, and Kalarus, Zbigniew

Subjects
*HEART failure treatment, *CARDIAC pacing, *OXYGEN consumption, *ECHOCARDIOGRAPHY, *HEALTH outcome assessment, *LEFT heart ventricle diseases, *FLUOROSCOPY
Abstract

Abstract: Background: The primary objectives of this study were to compare the implantation course of triple-site (double left–single right) and conventional cardiac resynchronization devices. The secondary target was to assess mid-term outcomes of both types of cardiac resynchronization therapy (CRT). Methods: Fifty-four patients with NYHA classes III–IV, left ventricular EF≤35% and QRS≥120 ms were included; 27 received triple-site pacemakers (TRIV group), 27 conventional CRT devices (BIV group). Procedural course, clinical data, QRS duration, echocardiographic parameters, peak oxygen consumption (VO2max) and 6-minute walking distance (6MWD) were screened for inter-group differences. Results: Procedure duration was higher in TRIV than in BIV group (197.6 vs. 137.6 min, P <0.001), fluoroscopy exposure and complication-rates were similar. After 3 months of CRT, triple-site pacing was associated with a more significant (P <0.05) NYHA class reduction (by 1.4 vs. 1.0 class, respectively), increase in VO2 max (2.9 vs. 1.1 mL/kg/min) and 6MWD (98.7 vs. 51.6 m) than conventional CRT. A higher EF and more improved intraventricular synchrony were observed in the TRIV than in the BIV group. The response rate in the TRIV group was 96.3% vs. 62.9% in the conventional group (P =0.002). Triple-site stimulation was an independent predictor of response to CRT (adjusted odds ratio 26.4, P =0.01). Conclusions: Triple-site resynchronization appears to be more beneficial than conventional CRT. Upgrade to triple-site CRT may be considered in non-responders to standard resynchronization. [Copyright &y& Elsevier]

Published
2009
Full Text
View/download PDF

30. Comparison of Outcomes of Direct Stenting Versus Stenting After Balloon Predilation in Patients With Acute Myocardial Infarction (DIRAMI)

Author

Gasior, Mariusz, Gierlotka, Marek, Lekston, Andrzej, Wilczek, Krzysztof, Zebik, Tadeusz, Hawranek, Michal, Wojnar, Rafal, Szkodzinski, Janusz, Piegza, Jacek, Dyrbus, Krzysztof, Kalarus, Zbigniew, Zembala, Marian, and Polonski, Lech

Subjects
*COMPARATIVE studies, *SURGICAL stents, *MYOCARDIAL infarction, *THROMBOLYTIC therapy, *PATIENTS
Abstract

Due to recent advances in stent design, stenting without balloon predilation (direct stenting) has become more extensively used in patients with acute myocardial infarction (AMI). We performed a randomized study with broad inclusion criteria and early randomization after presentation to compare direct stenting with stenting after balloon predilation in patients with AMI. A total of 248 patients was randomized. After exclusion of patients not suitable for stenting, the final study group comprised 217 patients. Direct stenting strategy was feasible in 88% of patients with no meaningful complications. Final Thrombolysis In Myocardial Infarction grade 3 flow (96% vs 94%), final Thrombolysis In Myocardial Infarction myocardial perfusion grade 2 or 3 (68% vs 61%), and average ST-segment resolution after the procedure (49% vs 51%) were similar in the direct stenting and predilation groups, respectively (p = NS). Rate of in-stent restenosis was higher in the direct stenting group (30% vs 16%, p = 0.024), which was due to a worse angiographic result after the procedure. At 5 years, a composite of cardiac death, reinfarction, and target lesion revascularization had occurred in 39% in the direct stenting group and 34% in the predilated group (p = 0.40). In conclusion, although at 5 years clinical outcome did not differ significantly between groups, direct stenting was associated with a higher incidence of in-stent restenosis at 1 year. Direct stenting did not improve epicardial and myocardial reperfusion indexes. Direct stenting strategy should not be recommended in all patients with AMI as an alternative strategy to stenting after predilation. [Copyright &y& Elsevier]

Published
2007
Full Text
View/download PDF

31. Comparison of heart rate variability between surgical and interventional closure of atrial septal defect in children.

Author

Bialkowski J, Karwot B, Szkutnik M, Sredniawa B, Chodor B, Zeifert B, Skiba A, Zyla-Frycz M, Kalarus Z, Białkowski, Jacek, Karwot, Blandyna, Szkutnik, Malgorzata, Sredniawa, Beata, Chodor, Beata, Zeifert, Bozena, Skiba, Alina, Zyla-Frycz, Maria, and Kalarus, Zbigniew

Abstract

This study was designed to compare reduced heart rate variability (HRV) in children with atrial septal defect (ASD) after surgical ASD closure with interventional (Amplatzer device) closure. Reduced HRV was observed in all children with ASD before treatment. HRV was further impaired 1 month after surgical ASD closure but not after catheter device closure. Three months after treatment, HRV indexes tended to normalize in both groups. [ABSTRACT FROM AUTHOR]

Published
2003

32. Comparison of heart rate variability between surgical and interventional closure of atrial septal defect in children

Author

Biallkowski, Jacek, Karwot, Blandyna, Szkutnik, Malgorzata, Sredniawa, Beata, Chodor, Beata, Zeifert, Bozena, Skiba, Alina, Zyla-Frycz, Maria, and Kalarus, Zbigniew

Subjects
*HEART beat, *ATRIAL septal defects in children, *MEDICAL equipment
Abstract

This study was designed to compare reduced heart rate variability (HRV) in children with atrial septal defect (ASD) after surgical ASD closure with interventional (Amplatzer device) closure. Reduced HRV was observed in all children with ASD before treatment. HRV was further impaired 1 month after surgical ASD closure but not after catheter device closure. Three months after treatment, HRV indexes tended to normalize in both groups. [Copyright &y& Elsevier]

Published
2003
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results